Most on here talking about commercialisation in 2023, Presentation gives marketing approval at end of 2025. Only real catalyst between then and now is futility analysis mid 2023.
Why would Sarepta do a deal now when no revenue/cash flows assuming they pass the trial until 2026? It’s not like there are heaps of other suitors they need to pre-empt.
Ann: Positive PDCO opinion and A$20m Placement, page-41
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.001(1.25%) |
Mkt cap ! $83.73M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.2¢ | 7.9¢ | $153.8K | 1.914M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 927041 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 218878 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |